Brivanib and FOLFOX in Hepatocellular Carcinoma: Finding the Common Themes Among Negative Trials

被引：10
作者：
Kelley, Robin K. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 28期
关键词：
MODIFIED RECIST; DUAL INHIBITOR; TUMOR RESPONSE; PHASE-III; CHEMOTHERAPY; DOXORUBICIN; RESISTANCE; MODELS; CANCER; CHEMOEMBOLIZATION;
D O I：
10.1200/JCO.2013.49.7941
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3483 / 3486
页数：4
相关论文
共 29 条
  • [1] Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
    Allen, Elizabeth
    Walters, Ian B.
    Hanahan, Douglas
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5299 - 5310
  • [2] Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
    Asghar, Uzma
    Meyer, Tim
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (03) : 686 - 695
  • [3] Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants
    Bargellini, Irene
    Bozzi, Elena
    Campani, Daniela
    Carrai, Paola
    De Simone, Paolo
    Pollina, Luca
    Cioni, Roberto
    Filipponi, Franco
    Bartolozzi, Carlo
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2013, 82 (05) : E212 - E218
  • [4] The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases
    Bhide, Rajeev S.
    Lombardo, Louis J.
    Hunt, John T.
    Cai, Zhen-wei
    Barrish, Joel C.
    Galbraith, Susan
    Jeyaseelan, Robert, Sr.
    Mortillo, Steven
    Wautlet, Barri S.
    Krishnan, Bala
    Kukral, Daniel
    Malone, Harold
    Lewin, Anne C.
    Henley, Benjamin J.
    Fargnoli, Joseph
    [J]. MOLECULAR CANCER THERAPEUTICS, 2010, 9 (02) : 369 - 378
  • [5] Cainap C, 2012, J CLIN ONCOL S34, V30
  • [6] Phase II Trials in Journal of Clinical Oncology
    Cannistra, Stephen A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3073 - 3076
  • [7] Cheng A, 2011, J CLIN ONCOL S, V29, p256s
  • [8] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
  • [9] MDR1 (MULTIDRUG-RESISTANCE) GENE-EXPRESSION IN HUMAN PRIMARY LIVER-CANCER AND CIRRHOSIS
    CHENIVESSE, X
    FRANCO, D
    BRECHOT, C
    [J]. JOURNAL OF HEPATOLOGY, 1993, 18 (02) : 168 - 172
  • [10] Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
    Edeline, Julien
    Boucher, Eveline
    Rolland, Yan
    Vauleon, Elodie
    Pracht, Marc
    Perrin, Christophe
    Le Roux, Catherine
    Raoul, Jean-Luc
    [J]. CANCER, 2012, 118 (01) : 147 - 156
123